Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Benzinga Newsdesk www.benzinga.com Negative 88.5%

Neg 88.5% Neu 0% Pos 0%

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.